Brentuximab in the Treatment of CD30-Positive Enteropathy-Associated T-Cell Lymphoma

Enteropathy-associated T-cell lymphoma (EATL) is a rare aggressive lymphoma that confers a poor prognosis with current treatment strategies. Given the rarity of this disease, prospective randomized trials are limited, andthus a standard validated treatment strategy is lacking. This report presents the disease course of a patient with EATL who was treated with single-agent brentuximab vedotin (BV), an anti-CD30 conjugated antibody.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the rationale for the management methods used in this case presentation
  • Describe the ideal management of a patient taking brentuximab for the treatment of CD30-positive enteropathy-associated T-cell lymphoma
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
02/18/2013
Course expires: 
02/18/2014
Cost:
$0.00

Waleed F. Khalaf, MD
Division of Hematology/Oncology,Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Meghan E. Caldwell, ACNP
Division of Hematology/Oncology,Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Nishitha Reddy, MD, MSCI
Division of Hematology/Oncology,Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Accreditation Period

Course opens: 
02/18/2013
Course expires: 
02/18/2014

Price

Cost:
$0.00
Please login or register to take this course.